Leadership Overview
Dexcel Pharma has 6 executives leading key functions including strategy, operations, information technology, finance, and medical affairs.
Committed to advancing global health through high-quality medication, Dexcel Pharma delivers value-added branded prescription drugs and generics to international markets while maintaining a focus on excellence in oral solid dosage manufacturing.
Committed to advancing global health through high-quality medication, Dexcel Pharma delivers value-added branded prescription drugs and generics to international markets while maintaining a focus on excellence in oral solid dosage manufacturing.
Leadership Roles at Dexcel Pharma
Dan Oren - President & Chief Executive Officer
Dan Oren, the President & Chief Executive Officer at Dexcel Pharma, directs the overarching corporate strategy and long-term vision for the organization. Overseeing the expansion of the company into diverse international markets, the President & Chief Executive Officer ensures that the development of branded prescription drugs and generics aligns with global regulatory standards. This leadership role involves managing complex relationships with distribution partners across the U.S., U.K., and Germany to maximize market penetration. By prioritizing innovation in oral solid dosage forms, Dan Oren drives the competitive positioning of the firm within the pharmaceutical landscape. The President & Chief Executive Officer maintains a focus on sustainable growth and operational excellence, ensuring that the company remains a leader in the industry while delivering high-quality therapeutic solutions to patients worldwide.
Ilan Oren - Co-Chief Executive Officer
Ilan Oren, the Co-Chief Executive Officer at Dexcel Pharma, manages the execution of strategic initiatives and internal organizational alignment. Focusing on the commercialization of the extensive product portfolio, the Co-Chief Executive Officer oversees the integration of manufacturing capabilities with market demand across various regions. This leadership role involves coordinating with cross-functional teams to optimize the supply chain and ensure the consistent delivery of over 85 products. By fostering a culture of efficiency and quality, Ilan Oren supports the company's mission to provide accessible healthcare solutions. The Co-Chief Executive Officer monitors performance metrics to ensure that all business units meet established growth targets. Through rigorous oversight of commercial operations, Oren strengthens the market presence of the firm and ensures that the organization remains responsive to the evolving needs of the global pharmaceutical sector.
Yaron Erez - Chief Financial Officer & Vice President
Yaron Erez, the Chief Financial Officer & Vice President at Dexcel Pharma, directs the financial planning, capital allocation, and fiscal reporting for the organization. Overseeing the economic health of the company, the Chief Financial Officer & Vice President ensures that resources are effectively distributed to support the development and commercialization of pharmaceutical products. This leadership role involves managing financial risks associated with international market expansion and currency fluctuations in regions like the U.K. and Germany. By implementing rigorous financial controls, Yaron Erez supports the long-term sustainability and profitability of the firm. The Chief Financial Officer & Vice President collaborates with other executives to evaluate investment opportunities in new dosage forms and manufacturing technologies. Through strategic financial management, Erez ensures that the company maintains the necessary capital to achieve its ambitious growth objectives.
Ziv Teresh - Chief Operating Officer & Vice President
Ziv Teresh, the Chief Operating Officer & Vice President at Dexcel Pharma, manages the day-to-day manufacturing operations and production efficiency of the company. Overseeing the facilities responsible for creating oral solid dosage forms, the Chief Operating Officer & Vice President ensures that all production lines meet stringent quality and safety standards. This leadership role involves optimizing manufacturing workflows to increase output and reduce lead times for global distribution partners. By focusing on process improvement and resource management, Ziv Teresh drives the operational success of the firm. The Chief Operating Officer & Vice President coordinates with the supply chain team to ensure that products reach international markets in a timely manner. Through the application of lean manufacturing principles, Teresh maintains the high standards required for the company's extensive portfolio of branded and generic medications.
Miri Peleg - Vice President, Chief Information Officer
Miri Peleg, the Vice President, Chief Information Officer at Dexcel Pharma, architects the digital infrastructure and technological framework supporting the company's manufacturing and distribution operations. Overseeing the implementation of advanced data systems, the Vice President, Chief Information Officer ensures the security and integrity of information across all international subsidiaries. This leadership role involves integrating digital solutions to streamline production processes and enhance supply chain visibility. By leveraging data analytics, Miri Peleg drives informed decision-making across the executive team, supporting the company's goal of operational excellence. The Vice President, Chief Information Officer manages the technological roadmap to ensure that the firm remains at the forefront of pharmaceutical manufacturing innovation. Through the deployment of robust IT strategies, Peleg facilitates seamless communication and data flow between global markets and the headquarters.
Esther Hagai - Chief Medical Officer
Esther Hagai, the Chief Medical Officer at Dexcel Pharma, directs the clinical development and medical strategy for the company's pharmaceutical portfolio. Overseeing the scientific integrity of all products, the Chief Medical Officer ensures that the development of new drugs adheres to the highest medical and ethical standards. This leadership role involves providing clinical guidance during the research and commercialization phases to ensure that all medications meet patient needs effectively. By monitoring clinical data and regulatory requirements, Esther Hagai supports the company's commitment to safety and efficacy in the pharmaceutical market. The Chief Medical Officer collaborates with the research and development teams to evaluate the therapeutic potential of new dosage forms. Through expert medical oversight, Hagai ensures that the firm maintains its reputation for quality and reliability in the global healthcare industry.
Explore Leadership Teams in Manufacturing
AbbVie Inc. is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines and health solutions that address some of the worlds most complex medical challenges. Headquartered in North Chicago, Illinois, the company operates internationally and focuses on advancing treatments that improve patient outcomes and overall quality of life. AbbVies scientific and commercial efforts are concentrated in several core therapeutic areas, including immunology, oncology, neuroscience, eye care, and medical aesthetics, along with other specialty areas where significant unmet medical needs exist. Through these focus areas, the company works to create therapies that help patients manage chronic, serious, and often life-altering diseases.
Company Leadership XY
MS
JN
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
Company Leadership ES
NB
Jazz Pharmaceuticals plc is a global biopharmaceutical company headquartered in Dublin, Ireland, founded in 2003. The company develops and commercializes medicines for serious diseases with limited treatment options, focusing on neuroscience, including sleep medicine and movement disorders, and oncology, including hematologic malignancies and solid tumors. Jazz maintains a global presence with offices and manufacturing facilities across the U.S., UK, Ireland, and Italy and advances its portfolio through internal R&D, acquisitions, and licensing partnerships.
Company Leadership
JU
RI
Vanda Pharmaceuticals, founded in 2003, is a biopharmaceutical research and development company focused on creating innovative medicines to improve patient lives. The company leverages advanced technologies including genetics and genomics to guide drug discovery, clinical trials, and commercial strategies. Vanda Pharmaceuticals specializes in developing novel therapeutic approaches and delivery methods for their pharmaceutical products. With operations across North America, Europe, and Asia, the company maintains a global presence in the pharmaceutical industry while continuing to advance medical research and drug development for various health conditions.
Company Leadership
KM
PJ
Frequently Asked Questions Regarding Dexcel Pharma Top Executives and Leadership Team
